Vali Barsan

Vali Barsan is an attending physician in oncology at Stanford University School of Medicine, with clinical expertise in leukemia, lymphoma, molecular diagnostic testing for relapsed cancers, and cancer immunotherapy Phase I trials. Currently involved in multiple roles, Vali Barsan serves as a clinical fellow at Kamau Therapeutics, and holds board director positions at ArsenalBio, Neuron23, Umoja Biopharma, and Karius, among others, focusing on innovative cancer treatment and precision medicine. Previous experience includes medical consulting roles at Illumina and Karius, as well as graduate research at MD Anderson Cancer Center. Vali Barsan's education includes a fellowship in Pediatric Hematology/Oncology and Stem Cell Transplantation from Stanford, a residency in Pediatrics, and an M.D. from Baylor College of Medicine, alongside a B.S. in Bioengineering from UC San Diego.